hwk-016
·Code: HWK-016
hwk-016: sourced relationships with 1 company · 1 clinical trial tracked.
hwk-016 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect hwk-016 to WHWK; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could hwk-016 → WHWK affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence2 indications · 0 study sponsors
Related indications
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Whitehawk Therapeutics, Inc. (WHWK) PROC | Phase 1 |
Clinical Trial Registry Records (1)
A Phase 1 First-in-Human Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.
Primary endpoint: Determine Maximum Tolerated Dose (MTD)
Interventionalopen265 targetStarted 2026-03Completion 2028-0212 sites · United StatesWhitehawk Therapeutics, Inc.
Frequently asked questions
Which companies have sourced relationships with hwk-016?
hwk-016 has dated SEC/FDA relationship records for Whitehawk Therapeutics, Inc..
How many clinical trials involve hwk-016?
BioSniper tracks 1 clinical trial involving hwk-016.